ArticleBiologics : targets & therapy2013
Erythropoiesis stimulating agents: approaches to modulate activity.
Article in Biologics : targets & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.The Cochrane database of systematic reviews · 2017Pooled it
- Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.The Cochrane database of systematic reviews · 2015Pooled it
- A short-term intervention of ingesting iron along with methionine and threonine leads to a higher hemoglobin level than that with iron alone in young healthy women: a randomized, double-blind, parallel-group, comparative study.European journal of nutrition · 2023Trial
- Development and Validation of an Efficient In vitro Bioassay for Potency Estimation of Recombinant Human Erythropoietin Formulations.Pharmaceutical research · 2026Article
- An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo.Protein science : a publication of the Protein Society · 2025Article
- A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders.iScience · 2022Article
- Association between Hematological Indicesand Disease Activity in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors for 24 Weeks.Medicina (Kaunas, Lithuania) · 2022Article
- The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review.Frontiers in pharmacology · 2022Review
- Unravelling the potential neuroprotective facets of erythropoietin for the treatment of Alzheimer's disease.Metabolic brain disease · 2022Review
- Insights into Potential Targets for Therapeutic Intervention in Epilepsy.International journal of molecular sciences · 2020Review
- Injectables and Depots to Prolong Drug Action of Proteins and Peptides.Pharmaceutics · 2020Review
- Neuroprotective effects of EpoL against oxidative stress induced by soluble oligomers of Aβ peptide.Redox biology · 2019Article
- Neuroprotective effect of a new variant of Epo nonhematopoietic against oxidative stress.Redox biology · 2018Article
- Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor.Neural regeneration research · 2017Review
- Development of an in vitro Bioassay for Recombinant Human Erythropoietin (rHuEPO) Based on Proliferative Stimulation of an Erythroid Cell Line and Analysis of Sialic Acid Dependent Microheterogeneity: UT-7 Cell Bioassay.The protein journal · 2017Article
- Erythropoietin and diabetes mellitus.World journal of diabetes · 2015Review
- Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2015Review
- The effect of erythropoiesis-stimulating agents in patients with therapy-refractory autoimmune hemolytic anemia.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2014Article
- A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPOJournal of pharmacy & pharmacognosy researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may be required to achieve required hemoglobin levels. Therefore, a need was identified in some anemic patient populations for erythropoiesis stimulating agents with longer half-lives that required less frequent dosing. This need led to the development of second generation molecules which are modified versions of rHuEPO with improved pharma-cokinetic and pharmacodynamic properties such as darbepoetin alfa, a hyperglycosylated analog of rHuEPO, and pegzyrepoetin, a pegylated rHuEPO. Third generation molecules, such as peginesatide, which are peptide mimetics that have no sequence homology to rHuEPO have also recently been developed. The various molecular, pharmacokinetic, and pharmacodynamic properties of these and other erythropoiesis stimulating agents will be discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.